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ABSTRACT. Purpose: Chromium treatment has been shown to improve glucose regu-
lation in some populations. The purpose of this study was to evaluate whether chromium
picolinate (CrPic) supplementation improves glucose regulation in overweight individ-
uals with binge-eating disorder (BED). Methods: In this double-blinded randomized pi-
lot trial, participants (N = 24) were randomized to high (HIGH, 1000 mcg/day, n = 8) or
moderate (MOD, 600 mcg/day, n = 9) dose of CrPic or placebo (PL, n = 7) for 6 months.
Participants completed an oral glucose tolerance test (OGTT) at baseline, 3 months,
and 6 months. Fixed effects models were used to estimate mean change in glucose area
under the curve (AUC), insulinAUC, and insulin sensitivity index (ISI). Results: Re-
sults revealed a significant group and time interaction (p < 0.04) for glucoseAUC, with
glucoseAUC increasing significantly in the PL group (p < 0.02) but decreasing signif-
icantly in the MOD group (p < 0.03) at 6 months. InsulinAUC increased significantly
over time (main effect, p < 0.02), whereas ISI decreased significantly over time (main
effect, p < 0.03). Conclusion: As anticipated, a moderate dose of CrPic was associated
with improved glycemic control, whereas PL was associated with decreased glycemic
control. It was unexpected that the improved glycemic control seen in the MOD dose
group was not seen in the HIGH dose group. However, although participants random-
ized to the HIGH dose group did not have improved glycemic control, they had better
glycemic control than participants randomized to the PL group. These findings support
the need for larger trials.
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Binge-eating disorder (BED) is a psychiatric disorder that has recently been
included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) as an independent eating disorder diagnosis for the first time (American
Psychiatric Association 2013). BED is characterized by recurrent episodes of binge
eating, defined as the consumption of an unusually large amount of food in a short
period of time accompanied with a feeling of loss of control over eating, in the ab-
sence of inappropriate compensatory behaviors. BED is the most prevalent eating
disorder, affecting 3.5% of adult women and 2% of adult men in the U.S. (Hudson
et al., 2007). BED is highly comorbid with several psychiatric and medical condi-
tions, including depression, metabolic syndrome (i.e., meeting at least three risk fac-
tors for arthosclerotic cardiovascular disease), and diabetes (Reichborn-Kjennerud
et al., 2004, Yanovski et al., 1993, Bulik, Sullivan, & Kendler, 2002, Grilo, White, &
Masheb, 2009). Notably, individuals with BED have significantly greater risk of de-
veloping components of the metabolic syndrome (e.g., abdominal obesity, dyslipi-
demia, hypertension, and abnormal glucose metabolism) independent of the risk of
obesity alone and type 2 diabetes (T2DM) than individuals without BED (Hudson
et al., 2010). Individuals with T2DM who also struggle with binge eating and/or de-
pression have worse diabetes-related complications and poorer diabetes outcomes
(Rotella et al., 2012, de Groot et al., 2001, Katon et al., 2009, Lin et al., 2010). For
example, in one study of individuals with T2DM, eating pathology was associated
with unsatisfactory glycemic control (Rotella et al., 2012).
Currently available options for BED treatment include several psychological
and pharmacological interventions (Berkman et al., 2015; Brownley et al., 2016).
Although some of these interventions are effective in helping patients reduce binge
eating and its related psychological distress and physical consequences, not all pa-
tients respond adequately in terms of achieving binge abstinence and mood and
metabolic stabilization. BED has historically been treated with medications such as
citalopram, fluoxetine, fluovoxamine, imipramine, orlistat, sertraline, sibutramine,
and more recently lixdexamfetamine (McElroy et al. 2015; McElroy et al., 2016).
However, many patients drop out of pharmacological BED treatment due to medi-
cation side effects. Side effects associated with these medications in the treatment of
BED include blurred vision, constipation, decreased libido, depression, dizziness,
dry mouth, fatigue, headache, increased urinary frequency, insomnia, nausea, ner-
vousness, sexual dysfunction, sedation, and somnolence (Brownley et al., 2007). Of
concern, little information exists regarding the treatment and prevention of T2DM
in individuals with BED. Although lifestyle interventions are effective, they are dif-
ficult to sustain (Korkiakangas, Alahuhta, & Laitinen, 2009). Drug treatments for
T2DM have numerous side effects and limited durability. Addressing these unmet
treatment needs in BED requires further investigation of novel interventions that
ultimately help patients achieve binge eating abstinence and healthy weight and
metabolic stabilization.
Chromium is an essential mineral that affects insulin and serotonin function-
ing and has the potential to also influence dopamine functioning (Davis & Vin-
cent, 1997, McCarty, 1994), making it a plausible candidate for treatment of the
complex patient with comorbid BED, depression, and T2DM. Prior studies have
shown that chromium supplementation attenuates weight gain and visceral fat ac-
cumulation in patients with T2DM and improves insulin sensitivity and glycemic
control in patients with T2DM, metabolic disorder, and polycystic ovary syndrome
(Martin et al., 2006, Albarracin et al., 2008). In addition, chromium supplementa-
tion reduced carbohydrate cravings and appetite in patients with atypical depres-
sion (Docherty et al., 2005). The dose of chromium studied affects treatment ef-
ficacy, although the optimal dosage level is unknown (Broadhurst & Domenico,
2006). Building on these findings and our understanding of the physiological and
psychological components of BED, the purpose of the present study was to evaluate
whether a high or moderate dose of chromium supplementation improves glucose
regulation in overweight individuals with BED. We hypothesized that high and
moderate doses of chromium supplementation would be associated with improved




A total of 220 potential participants self-referred to the study, of whom 43 passed
screening and 41 met initial eligibility criteria (i.e., age between 18 and 60, DSM-
IV criteria for BED, not pregnant or lactating, not currently engaged in other BED
treatments or using chromium). Out of the 41 patients assessed, three declined to
participate, and 10 met exclusion criteria. The remaining 28 eligible participants
met DSM-IV criteria for BED and all other inclusion criteria. Inclusion and exclu-
sion criteria are outlined in Table 1. This study was approved by the Institutional
Review Board at the University of North Carolina at Chapel Hill.
Procedure
The 28 eligible participants underwent a 1-month placebo run-in, after which four
participants were excluded due to placebo response. The remaining participants
TABLE 1. Inclusion and exclusion criteria
Inclusion Criteria
 DSM-IV criteria for BED
 BMI between 25 and 45
 Age between 18 and 60
Exclusion Criteria
 Current suicidal or homicidal intent
 Current psychiatric condition that requires acute care
 Currently using any medication known to control glucose metabolism or insulin or to
influence appetite or weight
 Fasting glucose level was >126 mg
 Current use of psychotropic medication was prohibited with the exception of stable
monotherapy involving citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine,
or sertraline
 Createnine level >1.0 for women or >1.2 for men
 Pregnant, planning on becoming pregnant during the study, or lactating
 Currently engaged in other BED treatments
 Current chromium use
Notes: DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; BED = Binge-Eating Disorder.
were randomized to HIGH (1000 mcg/day, n = 8) or MOD (600 mcg/day, n = 9)
dose of CrPic or PL (n = 7) for 6 months. The CrPic doses were chosen in light of
previous studies with non-BED populations. Specifically, a moderate dose of 600
mcg/day was chosen, as literature suggests that this level of dosage would be suffi-
cient for improving fasting glucose, insulin binding, and reducing depressive symp-
toms and cravings (Anderson et al., 1987, Davidson et al., 2003, Docherty et al.,
2005). A high dose of 1,000 mcg/day was chosen, as the literature suggests that this
level of dosage is needed to prevent weight gain in subjects with T2DM (Martin
et al., 2006). Adherence was assessed by asking participants to return all unused
pills at each study visit.
Participants who were randomized into the study completed an OGTT at base-
line, 3 months, and 6 months. Prior to each OGTT, participants fasted overnight.
For the OGTT, a glucose solution standardized for body weight at 1.75 g/kg was
consumed. Blood samples were obtained via an intravenous catheter at minute 0
(fasted) and then minutes 30, 60, 90, and 120 after ingestion of the glucose solution.
Nineteen participants completed all study visits, with four participants withdrawing
from the study due to personal reasons and one due to pregnancy.
Glucose was assayed with an Ortho Clinical Diagnostics Vitros 950 analyzer
(UNC Hospitals). Insulin was measured using a competitive radioimmunoassay
(Diagnostic Systems Labs, Webster, TX) at the UNC Endocrine Lab. Assay sensi-
tivity was 1.3 μIU/mL with a standard range of 5-300 μU/mL. Glucose and insulin
area under the curve (AUC) were calculated using the trapezoidal rule. ISI was
evaluated by the formula: 10,000 /
√
(fasting glucose × fasting insulin × mean glu-
cose × mean insulin) (Matsuda & DeFronzo, 1999). Fixed effect models with a ran-
dom intercept were used to estimate the mean change in glucoseAUC, insulinAUC,
and ISI over the 3-month and 6-month active treatment period.
RESULTS
Characteristics of the Sample
Our sample included 24 randomized participants. The mean age of the sample was
36.6 (SD 10.6) years and their mean BMI was 34.2 kg/m2 (SD 5.4). Most of the
sample was white (87.5%) and female (83.8%). Participants exhibited a mild level
of depression, as measured by the Quick Inventory of Depressive Symptomatol-
ogy Self-Report [mean (SD) = 6.8 (3.8)] and were nondiabetic [mean (SD) fast-
ing plasma glucose = 90.3 (9.4) mg/dL]. The mean HbA1c of the sample was 5.5.
There were no statistically significant differences between the HIGH, MOD, and
PL groups on any of these measures.
Outcomes
Figures 1–3 depict the results of our study. The analyses revealed a statistically sig-
nificant group and time interaction (p < 0.04) for glucoseAUC, with a statistically
significant increase in the PL group at 6 months (p < 0.02), but a statistically sig-
nificant decrease at 6 months in the MOD group (p < 0.03). From baseline to 6
months, glucoseAUC increased 12.6% in the PL group, decreased 10.1% in the MOD
dose group, and increased 6.5% in the HIGH dose group. InsulinAUC increased
FIGURE 1. Percent change in glucoseAUC from baseline to 6 months. AUC = area under
the curve.
FIGURE 2. Percent change in insulinAUC from baseline to 6 months. AUC = area under the
curve.
significantly over time (main effect, p < 0.02). From baseline to 6 months,
insulinAUC increased 58.0% in the PL group, increased 9.5% in the MOD dose
group, and increased 32.9% in the HIGH dose group. ISI decreased significantly
over time (main effect, p < 0.03). From baseline to 6 months, ISI decreased 42.6%
in the PL group, increased 13.6% in the MOD dose group, and decreased 24.1% in
the HIGH dose group.
DISCUSSION
The purpose of this study was to evaluate the effect of CrPic supplementation on
glucose regulation in patients with BED. In this small sample, a moderate dose of
CrPic supplementation was associated with improved glycemic control, whereas a
PL dose was associated with decreased glycemic control. Specifically, glucoseAUC
decreased in the moderate dose group but increased in the placebo group. All par-
ticipants and particularly those in the placebo group experienced an increase in
insulinAUC. ISI decreased significantly over time, with the largest magnitude de-
crease occurring in the PL group.
FIGURE 3. Percent change in ISI from baseline to six months. ISI = insulin sensitivity index.
GlucoseAUC increased in the PL group but decreased in the MOD group over
time. The significant decrease in the MOD group is consistent with other chromium
supplementation studies (Martin et al., 2006). However, it was unexpected that
the improved glycemic control seen in the MOD dose group was not seen in the
HIGH dose group. One explanation for this is that the individuals in the moderate
group could have experienced optimal improvement in glycemic control because
they had the highest Hba1c levels to begin with, as previous research has shown
that chromium provides the greatest benefits to individuals with higher Hba1c lev-
els (Albarracin et al., 2008). Alternatively, the results could have occurred due to
differences in binge frequency. The HIGH group had the highest number of binge
episodes at baseline. Although the HIGH group experienced a reduction in binge
frequency over the course of the trial, their number of binge episodes at the end of
treatment were still not as low as that of the MOD group. Finally, it is possible that
this unexpected finding occurred due to the limited statistical power of this study.
Additional adequately powered studies are warranted to evaluate chromium sup-
plementation for glycemic control in individuals with BED who are at increased
risk of metabolic disease. However, it is important to note that the magnitude of
increase was larger in the PL group than in the HIGH dose group.
InsulinAUC increased in all groups, with the largest magnitude increase occurring
in the placebo group. The overall increase in insulinAUC was also found in another
study evaluating chromium supplementation in individuals with T2DM (Martin
et al., 2006). The particularly high increase in insulinAUC in the placebo group is
evidence for worsening metabolic disease states in untreated patients with BED,
which is consistent with a longitudinal study on patients with BED conducted by
Hudson and collaborators (2010).
ISI decreased significantly over time, with the largest magnitude decrease oc-
curring it the placebo group. These results differ from the results of another study,
which found that CrPic supplementation has no effect on insulin sensitivity in obese
nondiabetic adults (Iqbal et al., 2009). It is possible that CrPic supplementation has
an effect on insulin sensitivity in some populations but not others.
Limitations of this study include its small and homogeneous self-referred sample,
the lack of an indicator of compliance (e.g., urinary chromium levels), and the fact
that the entire study was conducted in a single center. Despite limitations, this was
the first trial to evaluate different doses of CrPic on the improvement of glucose
regulation in individuals with BED.
In summary, this double-blind placebo-controlled six month pilot trial evaluated
whether CrPic supplementation improves glucose regulation in individuals with
BED. A 600 mcg/day dose of CrPic was correlated with improved glycemic con-
trol. On average, participants experienced an increase in insulinAUC and a decrease
in ISI. The largest insulinAUC increase and the largest ISI decrease occurred the PL
group. However, our sample was small and future adequately powered studies are
warranted.
Declaration of Interest: Dr. Bulik is a grant recipient from and a consultant for
Shire and has consulted for Ironshore.
FUNDING
This study was supported by a grant from the Brain & Behavior Foundation (for-
merly NARSAD) to Dr. Kimberly Brownley. Lauren Breithaupt and Margarita
Sala are supported by the National Science Foundation Graduate Research Fel-
lowship under Grant No. DGE-1356109. Any opinion, findings, and conclusions
or recommendations expressed in this material are those of the authors(s) and do
not necessarily reflect the views of the National Science Foundation. Dr. Cynthia
Bulik acknowledges funding from the Swedish Research Council (VR Dnr: 538-
2013-8864).
ABOUT THE AUTHORS
Margarita Sala is a Clinical Psychology PhD student at Southern Methodist Uni-
versity in Dallas, Texas. Lauren Breithaupt is a Clinical Psychology PhD student
at George Mason University in Fairfax, Virginia. Cynthia M. Bulik, PhD, is Distin-
guished Professor of Eating Disorders in the Department of Psychiatry and Pro-
fessor of Nutrition at the University of North Carolina at Chapel Hill. She is also
Professor of Medical Epidemiology and Biostatistics at Karolinska Institutet,
Stockholm, Sweden. Robert M. Hamer, PhD, was Professor of Psychiatry and Bio-
statistics at the University of North Carolina at Chapel Hill at the time of his un-
timely death on December 28, 2015. Maria C. La Via, MD, is Associate Professor
in the Department of Psychiatry at UNC Chapel Hill. Kimberly A. Brownley is As-
sociate Professor of Psychiatry at the University of North Carolina at Chapel Hill,
USA. Her research focuses on the psychobiology of appetite regulation including
the role of appetite-regulating gut peptides in weight and mood dysregulation in
psychiatric populations. She served as Principal Investigator on the present study
and lead author on the parent article that was published in 2013 (Brownley et al.,
2013).
REFERENCES
Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Chromium picolinate and biotin combination
improves glucose metabolism in treated, uncontrolled overweight to obese patients with type
2 diabetes. Diabetes Metab Res Rev. 2008;24(1):41–51. doi:10.1002/dmrr.755.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders
(5th ed.). Washington, DC, 2013.
Anderson RA, Polansky MM, Bryden NA, Bhathena SJ, Canary JJ. Effects of supple-
mental chromium on patients with symptoms of reactive hypoglycemia. Metabolism.
1987;36(4):351–355. doi:10.1016/0026-0495(87)90206-X.
Berkman ND, Brownley KA, Peat CM, Lohr KN, Cullen KE, Morgan LC, Bann CM, Wallace
IF, Bulik CM. Management and Outcomes of Binge-Eating Disorder [Internet]. Rockville
(MD): Agency for Healthcare Research and Quality (US); 2015 Dec. PMID:26764442.
Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in
diabetes mellitus—A review. Diabetes Technol Ther. 2006;8(6):677–687. doi:10.1089/dia.
2006.8.677.
Brownley KA, Berkman ND, Sedway JA, Lohr KN, Bulik CM. Binge eating disorder treatment:
a systematic review of randomized controlled trials. Int J Eat Disorder. 2007;40(4):337–348.
doi:10.1002/eat.20370.
Brownley KA, Berkman ND, Peat CM, Lohr KN, Cullen KE, Bann CM, Bulik CM. Binge-Eating
Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Jun 28.
doi: 10.7326/M15-2455. [Epub ahead of print] PMID:27367316.
Brownley KA, Von Holle A, Hamer RM, La Via M, & Bulik CM. A double-blind, randomized
pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and
Chromium (BEACh) study. Journal of Psychosomatic Research, 2013;75(1):36–42.
Bulik CM, Sullivan PF, Kendler KS. Medical and psychiatric morbidity in obese women with and
without binge eating. Int J Eat Disorder. 2002;32(1):72–78. doi:10.1002/eat.10072.
Davidson JR, Abraham K, Connor KM, McLeod MN. Effectiveness of chromium in atypical de-
pression: a placebo-controlled trial. Biol. Psychiatry. 2003;53(3):261–264. doi:10.1016/S0006-
3223(02)01500-7.
Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity.
Biochemistry. 1997;36(15):4382–4385. doi:10.1021/bi963154t.
de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depres-
sion and diabetes complications: a meta-analysis. Psychosom Med. 2001;63(4):619–630. doi:
10.1097/00006842-200107000-00015.
Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JRA. Double-blind, placebo-
controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohy-
drate craving. J.Psychiatr Pract. 2005;11(5):302–314. doi: 10.1097/00131746-200509000-00004.
Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates
in binge eating disorder. Int J Eat Disorder. 2009;42(3):228–234. doi:10.1002/eat.20599.
Hudson JI, Hiripi E, Pope HG, Jr., Kessler RC. The prevalence and correlates of eating disor-
ders in the National Comorbidity Survey Replication. Biol. Psychiatry 2007;61:(3):348–358.
doi:10.1016/j.biopsych.2006.03.040.
Hudson JI, Lalonde JK, Coit CE, Tsuang MT, McElroy SL, Crow SJ, et al. Longitudinal study
of the diagnosis of components of the metabolic syndrome in individuals with binge-eating
disorder. Am J Clin Nutr. 2010;91(6):1568–1573. doi:10.3945/ajcn.2010.29203.
Iqbal N, Cardillo S, Volger S, Bloedon LT, Anderson RA, Boston R, et al. Chromium picolinate
does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab
Syndr Relat Disord. 2009;7(2):143–150. doi: 10.1089/met.2008.0048.
Katon W, RussoJ, Lin EH, Heckbert SR, Karter AJ, Williams LH, et al. Diabetes
and poor disease control: is comorbid depression associated with poor medication
adherence or lack of treatment intensification? Psychosom Med. 2009;71(9):965–972.
doi:10.1097/PSY.0b013e3181bd8f55.
Korkiakangas EE, Alahuhta MA, Laitinen JH. Barriers to regular exercise among adults
at high risk or diagnosed with type 2 diabetes: a systematic review. Health Promot Int.
2009;24(4):416–427. doi:10.1093/heapro/dap031.
Lin EH, RutterCM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, et al. Depres-
sion and advanced complications of diabetes: a prospective cohort study. Diabetes Care.
2010;33(2):264–269. doi:10.2337/dc09-1068.
Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, et al. Chromium picoli-
nate supplementation attenuates body weight gain and increases insulin sensitivity in subjects
with type 2 diabetes. Diabetes Care. 2006;29(8):1826–1832. doi:10.2337/dc06-0254.
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance test-
ing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–1470. doi:
10.2337/diacare.22.9.1462.
McCarty MF. Enhancing central and peripheral insulin activity as a strategy for the treat-
ment of endogenous depression–an adjuvant role for chromium picolinate? Med Hypotheses.
1994;43(4):247-252. http://dx.doi.org/10.1016/0306-9877(94)90075-2.
McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdex-
amfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Re-
sults of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016
Apr;41(5):1251–60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9. PMID:26346638.
McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker
T, Jonas J, Gasior M. Efficacy and safety of lisdexamfetamine for treatment of adults with
moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015
Mar;72(3):235–46. doi: 10.1001/jamapsychiatry.2014.2162. PMID:25587645.
Reichborn-Kjennerud T, Bulik CM, Sullivan PF, Tambs K, Harris JR. Psychiatric and med-
ical symptoms in binge eating in the absence of compensatory behaviors. Obes Res.
2004;12(9):1445–1454. doi:10.1038/oby.2004.181.
Rotella F, Cresci B, Monami M, Aletti V, Andreoli V, Ambrosio ML, et al. Are psychopathologi-
cal features relevant predictors of glucose control in patients with type 2 diabetes? A prospec-
tive study. Acta Diabetol. 2012;49(Suppl 1):S179–184. doi:10.1007/s00592-012-0403-4.
Yanovski SZ, Nelson JE, Dubbert BK, Spitzer RL. Association of binge eating disorder and
psychiatric comorbidity in obese subjects. Am. J. Psych. 1993;150(10):1472–1479.
